Businessman with management background, father of a child with DMD.  Familiar with leading researchers and health professionals in the field of muscular dystrophy in Israel and abroad. Engages with top advisors in the field, providing access to insights and the latest data in DMD and related fields.  Oren launched ART Bioscience by securing funding from private foundations, government grants and commercial sources.

​

Nili earned her PhD in Computational Chemistry from the University of Southern California (USC, Los Angeles, USA) under the supervision of Arieh Warshel (Nobel Prize in Computational Chemistry) and her Bio-MBA from College of Management (Israel). She has over 15 years of leadership in drug discovery & development (EPIX, Dynamix, HepaRx, Kamari Pharma), including fundraising, multiple exits, as well as experience in establishing collaborations with large pharmaceutical companies (Amgen, Takeda, J&J, Merck).

Robert Besthof is a 25+ years global pharmaceutical “hands on” strategic and operational leader with a track record of building pipelines, and globally launching products. He worked for Eli Lilly, Wyeth and Pfizer across multiple strategic and operational senior leader roles.  In 2016 he established his consultancy focused on emerging biotechs, helping them define and implement differentiated investable paths for preclinical and clinical programs. He has led teams that generated a combined 18 POC’s and phase III programs across multiple therapeutic areas. 

Raanan Margalit founded Science in Action - a boutique preclinical CRO in 2010 after over 25 years of scientific practice in Academia and industry, where he gained knowledge and experience in immunology, cell biology, pathophysiology and extensive expertise in animal disease models.

Raanan specializes in the development and utilization of animal models for preclinical drug development, with special emphasis on autoimmune and inflammatory diseases, cancer and  neurodegenerative disorders. He has extensive experience in the development of drug candidates from inception through preclinical development towards clinical trials.